Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Opioids for management of breakthrough pain in cancer patients.

Potter MB.

Am Fam Physician. 2006 Dec 1;74(11):1855-7. Review. No abstract available.

2.

A new transmucosal fentanyl for breakthrough cancer pain.

Rospond RM.

Cancer Pract. 1999 Nov-Dec;7(6):317-20. Review. No abstract available.

PMID:
10732531
3.

Breakthrough pain: progress in management.

Lossignol DA, Dumitrescu C.

Curr Opin Oncol. 2010 Jul;22(4):302-6. doi: 10.1097/CCO.0b013e32833a873a. Review.

PMID:
20489619
4.

Fentanyl nasal spray (Lazanda) for pain.

[No authors listed]

Med Lett Drugs Ther. 2011 Dec 12;53(1379-1380):99-100.

PMID:
22173454
5.

Fentanyl buccal tablet (Fentora) for breakthrough pain.

[No authors listed]

Med Lett Drugs Ther. 2007 Sep 24;49(1270):78-9. No abstract available.

PMID:
17878889
6.

Cancer-related breakthrough pain.

Davies AN.

Br J Hosp Med (Lond). 2006 Aug;67(8):414-6. Review.

PMID:
16918095
7.

Fentanyl for breakthrough cancer pain--what's new?

Hagelberg NM, Olkkola KT.

Pain. 2010 Dec;151(3):565-6. doi: 10.1016/j.pain.2010.08.026. No abstract available.

PMID:
20817402
8.

Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.

Slatkin NE, Xie F, Messina J, Segal TJ.

J Support Oncol. 2007 Jul-Aug;5(7):327-34.

PMID:
17708123
9.

Integrated strategies for the successful management of breakthrough cancer pain.

Dickman A.

Curr Opin Support Palliat Care. 2011 Mar;5(1):8-14. doi: 10.1097/SPC.0b013e3283434515. Review.

PMID:
21325998
10.

A survey of transdermal fentanyl use in a major cancer center.

Hardy JR, Rees EA.

J Pain Symptom Manage. 1998 Apr;15(4):213-4. No abstract available.

PMID:
9601153
11.

Oral transmucosal fentanyl and sufentanil for incident pain.

Gardner-Nix J.

J Pain Symptom Manage. 2001 Aug;22(2):627-30. No abstract available.

PMID:
11503630
12.

Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.

Mystakidou K, Katsouda E, Parpa E, Vlahos L, Tsiatas ML.

Drug Deliv. 2006 Jul-Aug;13(4):269-76. Review.

PMID:
16766468
13.

Not so fast: the reformulation of fentanyl and breakthrough chronic non-cancer pain.

Markman JD.

Pain. 2008 Jun;136(3):227-9. doi: 10.1016/j.pain.2008.03.011. Epub 2008 Apr 1. No abstract available.

PMID:
18384960
14.

Review of the role of opioids in cancer pain.

Trescot AM.

J Natl Compr Canc Netw. 2010 Sep;8(9):1087-94. Review.

PMID:
20876545
15.

Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief.

Zeppetella G.

J Pain Symptom Manage. 2008 May;35(5):563-7. doi: 10.1016/j.jpainsymman.2007.06.012. Epub 2008 Feb 6.

PMID:
18258412
16.

Fentanyl intranasal. Breakthrough cancer pain: unsafe packaging.

[No authors listed]

Prescrire Int. 2010 Nov;19(110):251.

PMID:
21284356
17.

Alternatives to oral opioids for cancer pain.

Mercadante S, Fulfaro F.

Oncology (Williston Park). 1999 Feb;13(2):215-20, 225; discussion 226-9. Review.

18.

Pharmacotherapeutic management of breakthrough pain in patients with chronic persistent pain.

Fishbain DA.

Am J Manag Care. 2008 May;14(5 Suppl 1):S123-8. Review.

19.

Managing breakthrough cancer pain: a new approach.

Rhiner M, Kedziera P.

Home Healthc Nurse. 1999 Jun;17(6 Suppl):suppl 1-12; quiz 13-5. Review.

PMID:
10562023
20.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626

Supplemental Content

Support Center